Discovery Partners International Names Dr. David L. Coffen as Chief Scientific Officer.SAN DIEGO--(BUSINESS WIRE)--Nov. 18, 1998--Discovery Partners International today announced that David L. Coffen, Ph.D., former senior vice president of Chemistry at ArQule Inc. has joined the company as its chief scientific officer. Coffen will spearhead Discovery Partners' scientific evaluation of potential corporate partners and provide technology leadership for its pharmaceutical R&D collaborations, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Riccardo Pigliucci, chief executive officer of Discovery Partners. "David's addition to the management team will aid in both the scientific and business expansion of Discovery Partners' corporate umbrella," Pigliucci said. "His scientific expertise and first-hand experience in all aspects of drug discovery will be crucial as we move forward in establishing new collaborations with pharmaceutical companies and expanding those already in place. In addition to providing scientific direction for Discovery Partners, Dr. Coffen will also be an invaluable resource for the Company's scientific teams." Coffen has extensive knowledge in the field of synthetic organic chemistry and its application to pharmaceutical products, having spent 24 years of his career at Hoffmann-La Roche Inc., progressing to vice president, Molecular Sciences. His experience in developing the first combinatorial chemistry Combinatorial chemistry involves the rapid synthesis or the computer simulation of a large number of different but structurally related molecules. Introduction Synthesis of molecules in a combinatorial fashion can quickly lead to large numbers of molecules. program at Roche and overseeing the creation of a state-of-the-art robotic screening facility will be invaluable as he evaluates various key strategies in drug discovery platform developments at Discovery Partners. Coffen is the author of more than 100 papers, patents, monographs and book chapters. He serves on several scientific and technical advisory boards including, Dow Chemical, The Petroleum Research Fund (PRF PRF abbr. prolactin-releasing factor ), and The National Research Council of Canada The National Research Council Canada (NRC) is Canada's leading organization for scientific research and development. History NRC was established in 1916, mainly to advise the government. Then, in the early 1930s, laboratories were built in Ottawa. . Coffen is also on the Board of Directors of Organic Synthesis Organic synthesis is the construction of organic molecules via chemical processes. Organic molecules can often contain a higher level of complexity compared to purely inorganic compounds, so the synthesis of organic compounds has developed into one of the most important aspects of Inc. He received a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, , and a bachelor's of science in Chemistry from the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, . Discovery Partners International is focused on providing the best platforms, services and information available to augment the internal drug discovery efforts of pharmaceutical and biopharmaceutical companies. Subsidiaries include IRORI, a combinatorial chemistry instrument company, and ChemRx, a provider of chemistry services. The company is headquartered in La Jolla, Calif. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion